Transfusion medicine and safety.
Advances in safety of blood transfusion in clinical practice principally relate to preventing transfusion-transmitted infections (TTI). Epidemiological studies of TTI have resulted in the development, standardization, and implementation of an expanding array of immunoassays employed worldwide in routine screening of blood donated by voluntary blood donors. Exclusion of infected blood and their donors has remarkably reduced the risk of transmitting HBV, HCV, HIV-1/2, and HTLV-I/II infections. Nucleic acid tests (NAT) using enzymatic amplification of viral gene sequences have augmented the risk reduction in "window period" infections that are undetectable by the serological tests. Improved viral safety of transfusion therapy has led us to recognize the risk of bacterial contamination, especially in platelet concentrates stored optimally at room temperature. Besides the current effort devoted to microbial risk reduction, pathogen inactivation technologies promise reduction of the residual risk of known and emerging infectious agents. The clinical effectiveness of the foregoing measures, international harmonization/standardization of practices and procedures, and continued hemovigilance portend safest possible safety in the clinical practice of blood transfusion.
Dodd
Roger
R
American Red Cross Holland Laboratory, 15601 Crabbs Branch Way, Rockville, MD 20855, USA. dodd@usa.redcross.org
Kurt Roth
W
W
Ashford
Paul
P
Dax
Elizabeth M
EM
Vyas
Girish
G
D001803:Blood Transfusion / Q000592:standards / Q000639:trends*; D004866:Equipment Contamination / Q000517:prevention & control; D006403:Hematologic Tests / Q000592:standards / Q000639:trends; D006801:Humans; D007391:International Cooperation; D008828:Microbiological Techniques; D008954:Models, Biological; D012015:Reference Standards; D012449:Safety; D065227:Transfusion Reaction; D014777:Virus Diseases / Q000097:blood / Q000175:diagnosis / Q000517:prevention & control